Case Study: 54-year-old man with right-sided facial swelling
View web version
You are receiving this newsletter as a promotional effort on behalf of ChemotherapyAdvisor.com.
Click here to sign up to receive these newsletters on a regular basis.

Drug Showcase
KEYTRUDA® (pembrolizumab) for Unresectable or Metastatic Melanoma
This slideshow reviews drug information for KEYTRUDA® (pembrolizumab), indicated for unresectable or metastatic melanoma.
In the Clinic
Rolapitant Proves Effective for the Prevention of Chemotherapy-Induced Nausea and Vomiting
By
Viewpoint
Does Regulatory Bureaucracy Drive Disparities in Cancer Drug Access Around the World?

For more on the latest research and developments in oncology, visit our News section.

Case Study
54-year-old man presents with increasing right-sided facial swelling
Latest News
Biomarker May Predict Response to Sorafenib in Patients with Liver Cancer
DOST Imaging May Predict Breast Cancer Response to Chemotherapy
Aspirin Lowers Non-Metastatic Prostate Cancer Mortality

Want to receive emails specific to your profession and specialty? Click here to complete your profile.





Subscribe
If you were sent this by a colleague and wish to subscribe to Weekly highlights, please click here.

Unsubscribe
To unsubscribe from the Weekly Highlights click here.
To manage your entire Cancer Therapy Advisor profile login to your account.

You are subscribed as: %%EMAIL%%

To contact Haymarket Media for general questions or unsubscribe problems, please reply to this email.

All Cancer Therapy Advisor newsletters are sent from the domain "email.cancertherapyadvisor.com". When configuring e-mail or spam filter rules, please use this domain name.

Haymarket Media Inc
114 West 26th St 4th floor
New York, NY 10001